Biotech grants in the United States

Open

Funds research using data from expanded access to investigational drugs for people with ALS who are not eligible for any ongoing trial.

Open

Funds five university-based hubs that turn NIH-backed biomedical discoveries into products.

Open

Funds pilot and feasibility work that prepares a spinal cord injury approach for a future, larger clinical trial.

Open

Funds a spinal cord injury clinical trial that opens with a pre-application stage and calls for named community partners throughout.

Open

Funds spinal cord injury research from basic science through translation, open to investigators at any career stage.

Open

Funds translational spinal cord injury research toward clinical use, with a named community partner and about $2.08 million per award on average.

Open

Funds a clinical trial for service-connected eye injury or visual dysfunction, with a regulatory clock that runs past the application deadline itself.

Open

Funds basic-through-early-translational research on service-connected eye injury or visual dysfunction — clinical trials are not part of this one.

Open

Funds translational work turning a vision-research discovery into a drug, device or guideline ready for a definitive clinical trial.

Open

Pays entities up to $566,665 across three milestones to add shovel-ready cancer data or tools to NCI's CCDI ecosystem.

Open

Funds WARF-disclosed UW Madison inventions through patent and licensing preparation for market-ready transfer.

Open

Funds three years replicating a natural product's effect on its target in people, for teams that have already done the pharmacokinetics work.

Open

Funds three years of pharmacokinetics and target-engagement work on a botanical, probiotic or supplement, then three more if the milestones are met.

Open

Funds the mid-phase study that settles a natural product's dose, formulation or responder group before anyone commits to a multi-site efficacy trial.

Open

Pays tenure-track researchers up to $600,000 to build unproven cancer immunotherapy technology.

Open

Funds a continuation phase for medical research that already holds earlier DOD or DOW funding, from preclinical work through clinical trials.

Open

Supports translational research for FASD prevention and intervention, moving through feasibility and expansion milestones.

Open

Funds NSF-funded research teams translating discoveries toward field use through industry-aligned pathways and partnerships.

Open

Supports research teams and institutions for BCRP Breast Cancer Research in biotechnology and medical technology.

Open

Funds translational trauma-care research moving a mature idea toward better survival and care right after injury.

Open

Funds early feasibility work on a new orthopaedic treatment or device — the step that comes before any clinical study.

Open

Funds clinical research into combat orthopaedic injury at two levels — one observational, one requiring an actual clinical trial.

Open

Funds a rare-cancer idea that already has some data behind it, ready to move into its next stage of development.

Open

Funds shared rare-cancer research resources — tissue models, datasets or sharing infrastructure — built with named Patient Advocates.